Clinical Research Summary — Ozone Therapy Application Forms
Share
Important Notice — For Registered Health Practitioners Only
| This page is intended exclusively for registered health practitioners. It is not intended for patients or members of the general public. The content below summarises findings from peer-reviewed clinical research literature relating to ozone-oxygen therapy application forms. These are research-context findings only. They do not represent approved therapeutic indications in New Zealand and do not constitute claims made by OTMed NZ or HAB Herrmann Apparatebau GmbH regarding the efficacy of Medozon devices for any specific condition. The HAB Herrmann Medozon devices are notified to the Medsafe WAND database under the Medicines (Database of Medical Devices) Regulations 2003. WAND notification is a mandatory legal requirement — it is not a product approval or endorsement of therapeutic claims by Medsafe or the New Zealand Ministry of Health. Ozone-oxygen therapy is a complementary medical application. It should be used alongside — not as a replacement for — conventional medical treatment, and only within the practitioner's registered scope of practice under New Zealand law. |
About This Summary
Ozone-oxygen therapy is a complementary medical application, used in addition to conventional medicine. The following summarises published clinical research literature identifying the application forms supported by HAB Herrmann Medozon devices and the conditions studied in that research.
HAB Medozon devices support the following ozone-oxygen application forms, using the device in combination with appropriate accessories:
- Large autohaemotherapy (MAHT)
- Injection and syringe therapy
- External application of ozone with a bag
- Intestinal insufflation
The table below summarises the conditions and reported outcomes referenced in current peer-reviewed publications for each application form. These findings reflect the state of research literature and are provided to support clinical knowledge. They are not approved therapeutic indications in New Zealand.
For the full list of supporting references, see the Clinical References Research page here
Clinical Research Summary
Application form |
Researched Application |
Reported Outcome in Research Literature |
|
Large auto-haemotherapy (MAHT) |
Sudden hearing Loss | Hearing recovery |
| Acute Cerebral Infarction | Functional improvement | |
| Multiple Sclerosis |
Pain reduction Functional improvement |
|
|
Injection and syringe therapy |
Knee Osteoarthritis |
Pain reduction Functional improvement |
| Intervertebral Disc Hernia | Pain reduction | |
| Chronic Neuropathic Pain (Trigeminus Neuralgia, Herpes Zoster) | Pain reduction | |
|
External application of ozone with a bag |
Diabetic foot ulcer | Improved wound healing |
| Digital ulcer in systemic sclerosis | Improved wound healing | |
|
Intestinal insufflation |
Chemotherapy-induced peripheral neuropathy (CIPN) | Pain reduction |
Sources: Peer-reviewed publications referenced in the OTMed NZ Clinical Research References. Study types include randomised controlled trials, systematic reviews, observational studies and expert consensus documents. The quality and conclusions of individual studies vary — practitioners are encouraged to independently assess the evidence in the context of their clinical training and individual patient circumstances.
About the HAB Herrmann Medozon Devices
The HAB Herrmann Hyper Medozon Comfort and Medozon Compact are CE certified Class IIb ozone-oxygen therapy medical devices manufactured in Germany by HAB Herrmann Apparatebau GmbH. Both devices are notified to the Medsafe WAND database as required under New Zealand law and are available exclusively to registered health practitioners through OTMed NZ.For full device specifications and purchasing information, see: